Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

benralizumab (Fasenra)

Initiation (new start) criteria: Formulary benralizumab (Fasenra) will be covered on the prescription drug benefit for 6 months when the following criteria are met:

- Prescriber is an Allergist or Pulmonologist; -AND-
- Patient is at least 12 years of age; -AND-
- Patient has diagnosis of asthma with an eosinophilic phenotype (Type 2 asthma) defined as: an eosinophil count of at least 150 cells/microliter in the past 6 weeks OR an eosinophil count of at least at least 300 cells/microliter in the past 52 weeks. -AND-
- Patient has uncontrolled asthma defined as any of the following:
  i. Two or more exacerbations in the past 12 months requiring corticosteroids for more than 3 days;
  ii. One or more asthma exacerbation(s) leading to hospitalization in the past 12 months;
  iii. Asthma Control Test (ACT) is consistently less than 20 over past 12 months;
  iv. Dependence on daily oral corticosteroids for asthma control.
-AND-
- Patient has uncontrolled asthma despite good adherence (at least 75% over the past 3 months) to a regimen containing: a high dose inhaled corticosteroid (ICS), AND at least one additional asthma controller medication, such as a long-acting beta2 agonist (LABA); OR leukotriene receptor antagonist (LRTI [e.g., montelukast]); OR long-acting muscarinic antagonist (e.g., tiotropium); OR daily oral corticosteroids.
-AND-
- Benralizumab is to be used in combination with a high dose inhaled corticosteroid (ICS) AND at least one additional asthma controller medication, such as a: long-acting beta2 agonist (LABA); OR leukotriene receptor antagonist (LRTI [e.g., montelukast]); OR long-acting muscarinic antagonist (e.g., tiotropium); OR daily oral corticosteroids.
-AND-
- Benralizumab is NOT used in combination with any of the following: mepolizumab (Nucala), dupilumab (Dupixent), resilizumab (Cinqair), or omalizumab (Xolair).
-OR-
- Patient has been receiving benralizumab administered in clinic.
Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

benralizumab (Fasenra)

Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously: Formulary benralizumab (Fasenra) will be covered on the prescription drug benefit when the following criteria are met:

- Prescriber is an Allergist or Pulmonologist; -AND-
- Patient is at least 12 years of age; -AND-
- Patient is currently using benralizumab AND it is being used with an at least one additional asthma controller medication, such as an: inhaled corticosteroid (ICS), OR long-acting beta2 agonist (LABA); OR leukotriene receptor antagonist (LRTI [e.g., montelukast]); OR long-acting muscarinic antagonist (e.g., tiotropium); OR daily systemic corticosteroids.

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Formulary benralizumab (Fasenra) will be covered on the prescription drug benefit for 6 months when the following criteria are met:

- Prescriber is an Allergist or Pulmonologist; -AND-
- Patient is at least 12 years of age; -AND-
- Patient is currently using benralizumab AND it is being used with an at least one additional asthma controller medication, such as an: inhaled corticosteroid (ICS), OR long-acting beta2 agonist (LABA); OR leukotriene receptor antagonist (LRTI [e.g., montelukast]); OR long-acting muscarinic antagonist (e.g., tiotropium); OR daily systemic corticosteroids.

Continued use criteria (6 months after initiation): Formulary benralizumab (Fasenra) will continue to be covered on the prescription drug benefit when the following criteria are met:

- Evidence of improvement from baseline documented by any of the following:
  i. Fewer asthma exacerbations (defined as worsening of asthma that requires increase in inhaled corticosteroid dose or treatment with systemic corticosteroids);
  ii. Lowered daily dose of oral corticosteroids;
  iii. An increase of at least 3 points on the asthma control test (ACT);
  iv. Fewer asthma exacerbations, lowered daily dose of oral corticosteroids, or improved quality of life documented by the prescriber.